MTOR and prostate carcinoma: Treatment with NVP-BEZ235-a PI3K/mTOR dual inhibitor–was able to sensitize human castration resistant prostate cancer cell lines C4-2 and C4-2AT6 resistant to docetaxel, indicating that mTOR inhibition can even overcome chemoresistance in castration resistant prostate cancer [45].